Unstable angina and non-ST-segment elevation myocardial infarction
Conditions
Interventions
Group 1:Moderate-high intensity statin ± ezetimibe) + ilovolumab 140mg
Group 2:Moderate-to-high-intensity statin dose ± ezetimibe
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with coronary atherosclerotic heart disease who were admitted to hospital for the first time due to NSTE-ACS and received coronary angiography and PCI; 2. No perioperative complications within 48 hours after PCI; no or discontinuation of other antithrombotic therapy for at least 24 hours; 3. Aged >= 18 years; 4. HyperLDL-C: patients who have received statin ± ezetimibe (>=4 weeks) treatment, LDL-C> 2.2mmol/L; patients who have not received statin ± ezetimibe treatment, LDL-C > 4mmol/L; 5. Agree to join this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy or intolerance to PCSK9 inhibitors, and have used any kind of PCSK9 inhibitor; 2. Platelets 450 x 10^9/L, or other serious blood system diseases; 3. Patients with autoimmune diseases; 4. Patients who are undergoing or need long-term anticoagulation therapy; 5. Patients with liver and renal insufficiency (creatinine clearance rate <30ml/min, ALT/AST exceeding 3 times the upper limit of normal, or history of liver cirrhosis); 6. Combined with malignant tumor or serious infection; 7. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet aggregation rate;Blood lipids; | — |
Secondary
| Measure | Time frame |
|---|---|
| High-sensitivity C-reactive protein;Circulating platelet particles;Blood routine;Soluble P-selectin; | — |
Countries
China
Contacts
Public ContactChe Jingjin
The Second Hospital of Tianjin Medical University
Outcome results
None listed